Atorvastatin For The Reduction Of Ventricular Arrhythmias
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
To assess in patients with CAD [coronary artery disease] and an implantable defibrillator the
effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular
arrhythmia (ventricular tachycardia or ventricular fibrillation requiring ICD [implantable
cardioverter defibrillator] intervention) within one year after randomization.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.